ACE-031 Peptide: Myostatin Trap Biology, DMD Trials and Why It Was Halted
ACE-031 peptide guide covering ActRIIB-Fc decoy receptor biology, myostatin and activin inhibition, Duchenne muscular dystrophy trials and why it was halted.
ACE-031 is one of the most misrepresented names in muscle-focused peptide marketing. It is frequently sold or discussed as a "myostatin inhibitor peptide," yet it is not a peptide in the way that BPC-157 or a growth hormone secretagogue is. ACE-031, also known as ramatercept, is a recombinant Fc-fusion protein: the soluble extracellular domain of the activin receptor type IIB (ActRIIB) fused to the Fc portion of human IgG1. That distinction matters, because it changes how the molecule works, how long it lasts in the body and why its clinical development was stopped.
This guide is educational and not medical advice. ACE-031 is an investigational biologic that was never approved, and its sponsor discontinued development. Nothing here should be read as encouragement to source or self-administer it.
For broader context on how these molecules are categorized, see what peptides are and the related myostatin discussion in the Follistatin 344 guide.
ACE-031 At A Glance
| Question | Evidence-aware answer |
|---|---|
| What is it? | A soluble ActRIIB-Fc fusion protein (ramatercept), a decoy receptor, not a small peptide. |
| Developer | Acceleron Pharma, with partner Shire for the Duchenne program. |
| Target | Myostatin (GDF8), activin A, and related activin type II receptor ligands. |
| Main effect | Removes a natural brake on skeletal muscle, increasing lean and muscle mass. |
| Route | Subcutaneous injection in clinical trials. |
| Half-life | Long for the class, roughly 10 to 15 days after a single dose. |
| Status | Investigational and discontinued; halted in 2011, program ended in 2013. |
| Why stopped | Vascular adverse events: epistaxis, telangiectasias and gum bleeding. |
What ACE-031 Actually Is
Skeletal muscle size is controlled in part by signaling through the activin type II receptors, ActRIIA and ActRIIB. Several growth factors in the TGF-beta superfamily, including myostatin (also called GDF8) and activin A, bind these receptors and send a signal that limits muscle growth. Myostatin in particular is a powerful negative regulator: animals and people with myostatin loss-of-function mutations develop dramatic muscle hypertrophy.
ACE-031 exploits that biology in a direct way. Engineers at Acceleron Pharma took the part of the ActRIIB receptor that normally sits outside the cell and catches these ligands, then fused it to an immunoglobulin Fc region. The Fc portion does two things: it makes the protein dimerize into a high-avidity ligand trap, and it dramatically extends circulating half-life through recycling by the neonatal Fc receptor. The result is a soluble "decoy" receptor that floats in the bloodstream.
This is why calling ACE-031 a peptide is misleading. A peptide is a short chain of amino acids, usually a few dozen residues at most. ACE-031 is a glycosylated fusion protein closer in size and behavior to a monoclonal antibody. It is peptide-adjacent only because the peptide-research community discusses it alongside myostatin-targeting compounds.
Mechanism: A Myostatin And Activin Ligand Trap
The mechanism is best described as sequestration. Normally, myostatin, activin and several other ligands diffuse to muscle and bind membrane-bound ActRIIB, triggering an intracellular SMAD2/3 cascade that suppresses muscle protein accretion. ACE-031 intercepts those ligands in the circulation. Because the decoy carries the same binding domain as the real receptor, the ligands bind ACE-031 instead of the muscle-cell receptor. With the ligands trapped, the brake on muscle growth is released, satellite-cell and fiber dynamics shift toward anabolism, and lean mass rises.
Importantly, ACE-031 is not a selective myostatin antibody. The ActRIIB domain is promiscuous: it also binds activin A, GDF11 and, critically, the bone morphogenetic proteins BMP9 and BMP10. This broad binding profile is the same feature that explains both its potency and its eventual downfall. BMP9 and BMP10 are important for vascular integrity, and trapping them is the leading explanation for the bleeding and capillary changes that ended the program.
The same broad-trap concept appears with Follistatin 344, which also blocks myostatin while interacting with activin biology. Decoy receptors and follistatin variants are different molecular tools aimed at overlapping pathways.
Clinical Evidence
ACE-031 reached real human trials, which sets it apart from many compounds in this category that rest on cell or rodent data alone.
Phase 1 in healthy volunteers
A single-ascending-dose study by Attie and colleagues, published in Muscle & Nerve in 2013, randomized 48 healthy postmenopausal women to one subcutaneous dose of ACE-031 (0.02 to 3 mg/kg) or placebo. The drug was generally well tolerated, with injection-site erythema among the reported events. Exposure rose linearly with dose, and mean terminal half-life was about 10 to 15 days, consistent with an Fc-fusion design.
The pharmacodynamic signal was notable. At day 29, the 3 mg/kg group showed a statistically significant 3.3% increase in total-body lean mass by DXA and a 5.1% increase in thigh muscle volume by MRI. Serum biomarkers also pointed to effects on bone and fat metabolism. For a single subcutaneous dose, that is a meaningful demonstration that systemic myostatin/activin blockade can move human muscle mass.
Phase 2 in Duchenne muscular dystrophy
The lead clinical target was Duchenne muscular dystrophy (DMD), a fatal muscle-wasting disease where reducing the myostatin brake is an appealing strategy. In the randomized, double-blind, placebo-controlled, ascending-dose trial (ClinicalTrials.gov NCT01099761), ambulatory boys received subcutaneous ACE-031 every two to four weeks. Campbell and colleagues reported the results in Muscle & Nerve in 2017: 24 boys were enrolled, 18 to ACE-031 and 6 to placebo, using regimens of 0.5 mg/kg every four weeks and 1.0 mg/kg every two weeks.
The efficacy direction was encouraging but never confirmed. Investigators saw non-significant trends toward maintenance of six-minute walk test distance versus a decline on placebo, along with trends toward increased lean body mass and bone mineral density and reduced fat mass. Crucially, none of these reached statistical significance, because the study was stopped early.
Why The Program Was Halted
The defining fact about ACE-031 is that its development was stopped for safety, not abandoned for lack of effect. After the second dosing regimen in the DMD trial, non-muscle vascular adverse events emerged: epistaxis (nosebleeds), telangiectasias (small dilated surface blood vessels) and gum bleeding, along with skin erythema in some reports. These were not classed as serious or severe in the publication, and they resolved after stopping the drug, but they were considered unacceptable for a chronic pediatric therapy.
The mechanistic explanation ties back to the promiscuous ActRIIB trap. By mopping up BMP9 and BMP10 in addition to myostatin and activin, ACE-031 likely disturbed vascular homeostasis. In April 2011 Acceleron Pharma and partner Shire announced that the Muscular Dystrophy Association-supported trials had been halted, and in May 2013 the developers formally discontinued the ACE-031 program. An extension study (NCT01239758) was also closed out.
This history is a clear reminder that potent muscle effects and acceptable safety are not the same thing. The lesson pushed the field toward more selective approaches that try to block myostatin and activin without hitting BMP9/BMP10.
Safety Signals Reported
| Safety issue | What the trials showed |
|---|---|
| Epistaxis (nosebleeds) | Emerged in the DMD trial and contributed to halting dosing. |
| Telangiectasias | Dilated small vessels seen in dosed patients; linked to BMP9/10 trapping. |
| Gum and mucosal bleeding | Reported among the vascular events that ended the program. |
| Skin erythema | Noted in clinical reports, including injection-site reactions. |
| Off-target ligand binding | ActRIIB trap also binds BMP9/BMP10, a likely driver of vascular effects. |
| Unknown long-term risk | No long-term or approved safety data exist, since development stopped. |
Because ACE-031 was never approved and was discontinued, there is no established dosing, monitoring or risk-management framework for human use. General context on muscle and growth-axis risks is covered in growth hormone peptide side effects, but that does not substitute for the absence of a real safety package here.
How ACE-031 Compares
Against follistatin-based approaches: both target the myostatin/activin axis, but the molecular strategy differs. Follistatin is a natural binding protein, and Follistatin 344 is studied largely through gene-transfer research. ACE-031 is an engineered receptor decoy delivered as a subcutaneous protein. Both share broad-signaling concerns rather than clean, single-target action.
Against other muscle strategies: growth-axis peptides such as growth hormone secretagogues work upstream through GH and IGF-1 signaling, a different pathway from myostatin inhibition. ACE-031 acts downstream at the muscle-brake level. The two approaches are not interchangeable, and stacking marketing language across them ignores very different mechanisms and risk profiles.
Against later selective agents: the ACE-031 experience directly motivated more selective myostatin/activin blockers, including antibody approaches and engineered traps designed to spare BMP9/BMP10. The central design question that ACE-031 raised, how to remove the muscle brake without harming blood vessels, still defines this drug class.
A note on pharmacology: ACE-031's roughly 10-to-15-day half-life reflects its Fc-fusion design, which is far longer than a typical injectable peptide. For why molecular size and format change dosing frequency, see the peptide half-life guide.
Bottom Line
ACE-031 (ramatercept) is a soluble ActRIIB-Fc decoy receptor, not a classic peptide, and it remains one of the more instructive case studies in myostatin-targeted muscle therapy. It worked at the level of mechanism: a single dose increased lean mass and muscle volume in healthy volunteers, and the Duchenne trial showed encouraging body-composition trends.
It also failed at the level of safety. The same broad ActRIIB trap that blocked myostatin and activin also trapped BMP9 and BMP10, and the resulting vascular events, epistaxis, telangiectasias and gum bleeding, ended the program. Acceleron and Shire halted dosing in 2011 and discontinued ACE-031 in 2013. There is no approved product, no validated human dose and no long-term safety data. Anyone encountering ACE-031 sold as a muscle peptide should treat that framing as a marketing claim built on a discontinued investigational biologic, not on an established therapy.
References
Attie KM, et al. A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle & Nerve, 2013.
Campbell C, et al. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial. Muscle & Nerve, 2017.
ClinicalTrials.gov. A Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy (NCT01099761).
ClinicalTrials.gov. Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy (NCT01239758).
Neurology (AAN abstract, Acceleron Pharma). A Phase 2, Randomized, Placebo-Controlled, Multiple Ascending-Dose Study of ACE-031, a Soluble Activin Receptor Type IIB, in Boys with Duchenne Muscular Dystrophy. Neurology, 2012.
Lee SJ, et al. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. PNAS, 2005.
Frontiers in Pharmacology. Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy. 2021.